Kazia Therapeutics Ltd - Company Profile
Powered by 
All the data and insights you need on Kazia Therapeutics Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Kazia Therapeutics Ltd Strategy Report
- Understand Kazia Therapeutics Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kazia Therapeutics Catalyst Calendar
Proactively evaluate Kazia Therapeutics Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Kazia Therapeutics Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Dec 2019 | Phase I Trial Results | Kazia Therapeutics Ltd; St. Jude Children’s Research Hospital Inc | KZA | paxalisib | Oncology | Anaplastic Astrocytoma; Astrocytoma; Brain Tumor; Central Nervous System (CNS) Tumor; Glioblastoma Multiforme (GBM); Glioma; Pediatric Diffuse Intrinsic Pontine Glioma | Company Press Release |
| 31 Dec 2019 | Phase II Trial Results | IQVIA Holdings Inc; Kazia Therapeutics Ltd | IQV; KZA | paxalisib | Oncology | Brain Cancer; Glioblastoma Multiforme (GBM) | Company Press Release |
| 01 Dec 2019 | Phase I Trial Initiation | Kazia Therapeutics Ltd; Memorial Sloan Kettering Cancer Center | KZA | paxalisib | Oncology | Brain Cancer; Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis); Solid Tumor | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer